The Trump administration has executed one of the most consequential federal adjustments to American cannabis policy in decades, reclassifying state-licensed medical marijuana and FDA-approved cannabis products from the most restrictive Schedule I category to the less stringent Schedule III. Acting Attorney General Todd Blanche signed the order on Thursday, placing these products alongside drugs such as ketamine and codeine-based painkillers, and formally acknowledging a medical utility that federal law had long denied. Viewed from Washington, the move is framed as a pragmatic realignment: it does not legalise marijuana federally, but it removes bureaucratic hurdles to research and signals a recognition that the war on drugs, at least as applied to cannabis, is being recalibrated.

Blanche has also scheduled a hearing for June 2026 to consider broader rescheduling of all marijuana, a process ordered by President Trump in December and intended to expand patient access and scientific inquiry. Analysts in London note that this step, while modest, carries symbolic weight for international drug control regimes, as the United States remains a leading voice in United Nations narcotics conventions. Rescheduling under the Controlled Substances Act does not override state prohibition laws, however, and enforcement patterns remain starkly uneven.

A map published in the American press showing states with the highest marijuana arrest rates underscores that the order leaves local policing untouched, with arrests still concentrated in jurisdictions where cannabis remains illegal at the state level. Three-quarters of Americans now live in a state where marijuana is legal for medical or recreational use, yet federal classification had long created a legal and commercial limbo. The immediate effect of the rescheduling is to ease restrictions on clinical trials and to allow state-licensed medical dispensaries to operate with less fear of federal prosecution.

The broader hearing next year will test whether the momentum toward normalisation can overcome residual political and institutional resistance, and whether the rest of the world’s largest economy is prepared to follow the trajectory already charted by a majority of its states.